Europe Proteomics Research Report 2025: Market Insights, Competitive Landscape and Forecasts 2024-2034 Featuring Biognosys, DiaSorin, Merck, Oxford Expression Technologies
The Europe proteomics market is expected to rise to $27.43 billion by 2034 from $8.77 billion in 2024, with a CAGR of 12.07%. Driving this growth are advancements in mass spectrometry and next-gen sequencing technologies enhancing protein analysis precision. The increased focus on personalized healthcare, catalyzed by biomarker discovery and disease profiling, amplifies demand. Support from EU funding, public-private partnerships, and strategic alliances further propels market expansion. Europe's aging population and rising chronic diseases underscore the importance of proteomics in diagnostics and early detection. Key players include Biognosys AG, DiaSorin S.p.A., and Merck KGaA.
European Proteomics Market
Dublin, June 26, 2025 (GLOBE NEWSWIRE) -- The "Europe Proteomics Market: Focus on Offerings, Application, and Country - Analysis and Forecast, 2024-2034" report has been added to ResearchAndMarkets.com's offering.The Europe proteomics market is projected to reach $27.43 billion by 2034 from $8.77 billion in 2024, growing at a CAGR of 12.07% during the forecast period 2024-2034. Advances in mass spectrometry and next-generation sequencing technologies, which provide ever-increasing precision in protein analysis, are driving the proteomics market's growth in Europe. Demand is further increased by a rise in personalised healthcare activities, which are fuelled by initiatives to find new biomarkers and improve disease profiling.
New proteomic applications are being accelerated by strong research funding from EU programs, expanding public-private partnerships, and strategic alliances between hospitals, biotech companies, and academia. In the meantime, Europe's ageing population and increasing prevalence of chronic diseases highlight the need for better diagnostics and early detection techniques, solidifying proteomics as a key component of the region's clinical innovation and life-science R&D environment.The market for proteomics in Europe is growing rapidly as more and more clinical labs, pharmaceutical companies, and life science researchers realise how effective protein-level analysis is in understanding disease causes, finding biomarkers, and speeding up drug development. Regional vendors and service providers are launching integrated systems that optimise workflows from sample input to data interpretation, driven by ongoing advancements in high-resolution mass spectrometry, microfluidic sample preparation, and advanced bioinformatics. The need for both discovery-scale and targeted proteomics solutions is being driven by the acceleration of translational projects in oncology, immunology, and neurodegeneration through public and private funding streams, ranging from national research efforts to Horizon Europe funds.By increasing access to state-of-the-art single-cell and spatial proteomics techniques, academic-industry clinic partnerships and consortia have made it possible for researchers to map cellular heterogeneity within tissue microenvironments and identify new therapeutic targets. Clinical laboratories are laying the groundwork for wider regulatory approval and reimbursement by progressively validating multiple response monitoring assays and label-free quantification for companion diagnostics and patient stratification. Infrastructure investments in core facilities and data-analysis skills are solidifying proteomics as a key component of personalised and precision medicine plans throughout Western Europe, the Nordics, and rising Eastern European hubs.In the future, market players expect that further standardisation of protocols, improved interoperability between multi-omics data streams, and expanding collaborations with cloud computing providers will reduce entry barriers and open up new avenues for vaccine development, biomarker validation, and real-time therapeutic efficacy monitoring.
How can this report add value to an organization?Product/Innovation Strategy: The Europe proteomics market has been extensively segmented based on various categories, such as offering, application, and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.Competitive Strategy: The Europe proteomics market has numerous established players with product and service portfolios. Key players in the Europe proteomics market analyzed and profiled in the study involve established players offering proteomics products and services.
Europe Proteomics Market Trends, Drivers and Challenges
Trends
Growing integration of high-resolution mass spectrometers with single-cell and spatial proteomics workflows
Expansion of multi-omics platforms combining proteomics with genomics and metabolomics
Increased adoption of label-free quantitation and data-independent acquisition for deeper proteome coverage
Emergence of cloud-based bioinformatics and AI-driven data analysis pipelines
Rising use of targeted proteomics (PRM/MRM) in clinical assay development
Drivers
Strong EU and national funding programmes supporting biomarker discovery and translational research
Demand for precision medicine solutions, including companion diagnostics and stratified patient care
Growth of academic-industry partnerships and consortia accelerating technology validation
Regulatory encouragement for advanced safety and efficacy testing in drug development
Pressure to improve early-stage disease detection and monitor therapeutic responses
Challenges
High capital and operational costs for state-of-the-art instrumentation and specialized personnel
Complex sample preparation workflows and variability across laboratories
Data management bottlenecks due to massive proteomic datasets and lack of harmonized standards
Limited clinical validation and regulatory pathways for proteomics-based diagnostics
Need for robust quality-control frameworks and inter-laboratory reproducibility studies
Key Market Players and Competition SynopsisThe companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, type portfolio, and market penetration.Some prominent names in the Europe proteomics market include:
Biognosys AG
DiaSorin S.p.A.
Merck KGaA
Oxford Expression Technologies Ltd.
Key Attributes:
Report Attribute
Details
No. of Pages
87
Forecast Period
2024 - 2034
Estimated Market Value (USD) in 2024
$8.77 Billion
Forecasted Market Value (USD) by 2034
$27.43 Billion
Compound Annual Growth Rate
12.0%
Regions Covered
Europe
Key Topics Covered: Executive SummaryScope and Definition1 Market1.1 Market Outlook1.1.1 Comparative Advantages and Disadvantages of Proteomics Over Other Omics1.1.2 Proteomics Techniques by Introduction with Principles and Advantages/Limitations1.2 Key Findings1.3 Europe Proteomics Market Scenario1.3.1 Realistic Scenario1.3.2 Optimistic Scenario1.3.3 Pessimistic Scenario1.4 Industry Outlook1.4.1 Supply Chain Overview1.5 Trends: Current and Future Impact Assessment1.5.1 Increasing Automation for End-to-End Proteomics Workflow1.5.2 Significant Number of Collaborations among Market Players1.5.3 Growing Proteomics Research to Identify Disease Biomarkers1.6 Patent Analysis1.6.1 Patent Filing Trend (by Country, Year)1.7 Regulatory Framework1.7.1 European Union (EU)1.7.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.1.1.1 EU Medical Device Regulation1.7.1.1.2 EU In Vitro Diagnostic Regulation1.7.1.2 Regulatory Requirements for Clinical Proteomics Labs in the EU1.8 Product Benchmarking1.9 Market Dynamics Overview1.9.1 Market Drivers1.9.1.1 Increasing Prevalence of Chronic Diseases1.9.1.2 Increasing Technological Advancements1.9.1.3 Advancements in Personalized Medicine and Drug Discovery1.9.2 Market Restraints1.9.2.1 Shortage of Skilled Professionals1.9.2.2 Complexity in Analyzing Data of Proteomics Research1.9.3 Market Opportunities1.9.3.1 Progress in Nanoproteomics Platforms to Enhance and Thoroughly Analyze Natural Protein Complexes2 Proteomics Market (by Region), $Million, 2022-20342.1 Regional Summary2.2 Europe2.2.1 Regional Overview2.2.2 Driving Factors for Market Growth2.2.3 Factors Challenging the Market2.2.4 Europe Proteomics Market, by Application2.2.5 Europe Proteomics Market, by Offering2.2.5.1 Europe Proteomics Market, by Product2.2.6 France2.2.6.1 France Proteomics Market, by Application2.2.6.2 France Proteomics Market, by Offering2.2.6.2.1 France Proteomics Market, by Product2.2.7 Italy2.2.7.1 Italy Proteomics Market, by Application2.2.7.2 Italy Proteomics Market, by Offering2.2.7.2.1 Italy Proteomics Market, by Product2.2.8 Germany2.2.8.1 Germany Proteomics Market, by Application2.2.8.2 Germany Proteomics Market, by Offering2.2.8.2.1 Germany Proteomics Market, by Product2.2.9 U.K.2.2.9.1 U.K. Proteomics Market, by Application2.2.9.2 U.K. Proteomics Market, by Offering2.2.9.2.1 U.K. Proteomics Market, by Product2.2.10 Spain2.2.10.1 Spain Proteomics Market, by Application2.2.10.2 Spain Proteomics Market, by Offering2.2.10.2.1 Spain Proteomics Market, by Product2.2.11 Rest-of-Europe2.2.11.1 Rest-of-Europe Proteomics Market, by Application2.2.11.2 Rest-of-Europe Proteomics Market, by Offering2.2.11.2.1 Rest-of-Europe Proteomics Market, by Product3 Markets - Competitive Benchmarking & Company Profiles3.1 Proteomics Market: Competitive Landscape3.1.1 Corporate Strategies, January 2022-December 20243.1.2 Partnerships, Alliances, and Business Expansions3.1.3 Mergers and Acquisitions3.1.4 New Offerings3.2 Company Profiles3.2.1 Overview3.2.2 Top Products/ Services3.2.3 Top Competitors3.2.4 Target Customers3.2.5 Key Personnel3.2.6 Analyst View4 Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/jkxf01
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
European Proteomics Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
RH Stock Slides 23% in 3 Months: Should You Buy the Dip or Wait?
RH RH, previously known as Restoration Hardware, is a luxury retailer in the home furnishing space, whose share price performance has dropped 23.2% in the past three months compared with the Hoya Capital Housing ETF (HOMZ) index's 4.9% decline. HOMZ is an exchange-traded fund that offers a diversified glimpse of the U.S. residential housing industry through 100 companies across homebuilding, rental operators, home improvement, furnishings, mortgage services and real estate tech, to name a few. Image Source: Zacks Investment Research This California-based company's prospects are currently ailing from the ongoing softness in the country's housing market. RH's business is directly related to housing demand patterns, as softness in housing demand weakens renovation and home furnishing demand, especially in luxury. Moreover, the ambiguity surrounding the implementation of tariffs is adding to its concerns, alongside the increasing expense structure due to its ongoing brand expansion and elevation has been trailing behind the other renowned market players, including Williams-Sonoma, Inc. WSM, Ethan Allen Interiors Inc. ETD and Arhaus, Inc. ARHS, during the past three months when considering the share price performance. Even though Williams-Sonoma, Ethan Allen and Arhaus are standing above RH, their share price performance has also tumbled 3.4%, 1.7% and 9.2%, respectively, during the said time on the brighter side, the long-term prospects of RH seem appealing thanks to the strategic investments it is undergoing across its brand portfolio. The company is realizing incremental benefits from its global expansion efforts, apart from its product transformation and platform enhancement activities. Also, its recent sourcing shift strategies to minimize tariff impacts highlight prosperous long-term visibility. Favorable Global Trends: RH has been witnessing robust demand trends in the global market, especially in Europe. Across Europe, the market remained robust during the first quarter of fiscal 2025, with demand growing 60% across RH Munich and RH Dusseldorf. Besides, the company continues to witness demand acceleration in its noncomparable galleries, RH Brussels and RH Madrid. Amid all the uncertainties, RH believes that its luxury brand positioning and unique aesthetics have emanated a strong international appeal and, in the pursuit of global expansion, will provide it with a substantial opportunity to build brand image over RH is optimistic about its opening in Paris, with the gallery on the Champs Élysées, which is expected to open in September 2025, alongside another two openings in London and Milan in 2026. After the robust trends witnessed across its European business, RH expects to continue making meaningful investments in this market to boost further growth and profitability. In the upcoming years, RH expects to open RH Sydney, The Gallery in Double Bay, in Resourcing Efforts: With the ongoing tariff-related risks lingering in the market, RH is positioning itself to weather the storm when it arrives. The company recently highlighted that it is currently focusing on shifting its sourcing out of China with the expectation of receipts reducing from 16% in the first quarter of fiscal 2025 to 2% in the fourth quarter of the same year. Besides, the company has successfully resourced a significant portion of its upholstered furniture to its North Carolina factory. By the end of 2025, it projects 52% of its upholstered furniture to be produced in the United States and 21% in & Platform Enhancement Strategies: RH has been emphasizing several strategic initiatives to evolve from a home furnishings retailer to a luxury lifestyle brand over time. The initiatives include its focus on production elevation or transformation and retail platform expansion. It aims to continue elevating its products' design and quality while opening large, immersive Design Galleries, which blur the line between retail and RH highlighted the launch of its 2025 RH Outdoor Sourcebook, the new RH Interior Sourcebook and the RH Modern Sourcebook, which offer collections including furniture, textiles, lighting, rugs and much more. The company remains optimistic about the introduction of its new design aesthetic, Japandi, that amalgamates the essence of Japanese serenity and Scandinavian into 2025, for the remainder of the year, RH expects to open seven Design galleries at locations including RH Montreal, RH Paris, RH Detroit, RH Manhasset, RH San Diego and RH Palm Desert. In June 2025, RH opened its freestanding RH outdoor gallery, expanding its brand presence in East Hampton. In the long term, the company's platform expansion plans include opening seven to nine new galleries annually, with two to three Design Studios or Outdoor galleries, or new concept galleries per year. RH's earnings estimates for fiscal 2025 have trended upward in the past 30 days to $10.87 per share, which indicates robust 101.7% year-over-year growth. The analysts' sentiments remain bullish for the year, backed by the in-house strategies RH is pulling off to counter the market risks. EPS Trend Image Source: Zacks Investment Research However, even with the earnings estimates for fiscal 2026 having moved down in the past 30 days to $14.77 per share, the estimated figure indicates 35.9% year-over-year growth. RH stock is currently trading at a forward 12-month price-to-earnings (P/E) ratio of 15.04X. This is compared with the forward 12-month P/E ratios of 18.23X, 10.64X, and 19.22X at which Williams-Sonoma, Ethan Allen and Arhaus are currently trading. The discounted valuation of the stock, compared with two of the other market players, looks promising for investors. The housing market directly influences the revenue visibility and profitability of RH, as they are directly related to each other. With the current housing market softness in the United States, the benefits from the domestic market seem depressed for the company. As homebuyers are navigating through affordability concerns, new home sales remain suppressed, with renovation activities being on the dimmer side due to the inflationary the earnings call of the first quarter of fiscal 2025, RH highlighted the adverse impacts it faced due to the significant and unexpected Liberation Day tariffs announced on April 2, 2025. It believes that this sudden surge will hurt its second quarter of fiscal 2025 revenues by six percentage points, accompanied by ripple effects into order fulfillment and even though the ongoing in-house strategies are elevating RH's prospects, it is hitting hard on its expense structure. During the first quarter of fiscal 2025, the selling, general & administrative expenses (as a percentage of total net revenues) expanded 80 bps year over year to 36.8%, mainly due to elevated advertising costs related to the circulation of the Spring 2025 RH Interiors Sourcebook. Furthermore, during the quarter, the company witnessed an increase in other product costs, which partially impacted the margins. The chart below shows the SG&A expense trend in the past year. Image Source: Zacks Investment Research As discussed above, RH is undergoing strategic efforts to weather the market uncertainties in the form of tariff-related risks, inflationary pressures and housing market softness. Given the nature of its business, RH is grappling with the current softness in the U.S. housing its product elevation and platform expansion strategies, alongside robust trends across the European market, are boding well for its prospects. Although in the short term, RH is expected to witness a slight setback, in the long term, the growth trends remain bright, as witnessed from the earnings expectation taking any decisions regarding RH stock, investors must weigh both sides of the market currently. Thus, based on the discussion, it is prudent for existing investors to retain this Zacks Rank #3 (Hold) company's shares for now, whereas new investors might want to wait for a more favorable entry can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Williams-Sonoma, Inc. (WSM) : Free Stock Analysis Report RH (RH) : Free Stock Analysis Report Ethan Allen Interiors Inc. (ETD) : Free Stock Analysis Report Arhaus, Inc. (ARHS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Miami Herald
an hour ago
- Miami Herald
Amid declining EV sales, Tesla fires vice president of manufacturing
June 26 (UPI) -- Tesla CEO Elon Musk has fired the carmaker's vice president of manufacturing and operations following a falloff in auto sales in the nation's largest markets this year. Omead Afshar oversaw more than a half dozen upper-level employees in the company, including Troy Jones, Tesla's vice president of sales in North America, and Joe Ward, vice president of the Europe, Middle East and Africa region. The firing was first reported by Bloomberg News. Afshar is the second high-level employee to leave the company recently. His termination follows the resignation of Milan Kovac, who was the company's head of its Optimus humanoid robotics program. Kovac said in a post on X that he was leaving Tesla to spend more time with his family. Musk later thanked Kovac publicly for his time with the company. In 2022, Afshar was the subject of an internal investigation at Tesla that focused on his involvement in trying to secure construction materials for a secret project for Musk that included hard-to-get glass. Prior to his job as Tesla vice president, Afshar worked for SpaceX, Musk's aerospace company. Afshar's X account, which had not been updated, said he still works for Tesla, and he praised Musk for his leadership and work ethic following the launch of the company's Robotaxi service in Austin, Texas. "Thank you, Elon, for pushing us all," Afshar wrote. Tesla's stock price has dropped 19% this year, and took an especially hard hit following Musk's association with President Donald Trump, who appointed Musk to oversee the Department of Government Efficiency. DOGE took a broad and aggressive approach to eliminating federal employees, downsizing federal agencies and ending diversity, equity and inclusion programs at some of the nation's largest companies and universities. The company sold fewer cars in 2024 than it did in 2023, the first time sales dropped since Tesla began mass producing EVs. Its profits fell 71% in the first quarter of 2025. European sales dropped 28%, and dropped for a fifth straight month in May. The European Automobile Manufacturers Association said buyers are shifting to cheaper Chinese models. Copyright 2025 UPI News Corporation. All Rights Reserved.


UPI
2 hours ago
- UPI
Amid declining EV sales, Tesla fires vice president of manufacturing
A row of Teslas charge at a Tesla power station (2018). The company announced on Thursday that it sold fewer cars in 2024 than it did in 2023, the first time sales dropped since Tesla began mass producing EVs. Its profits fell 71% in the first quarter of 2025, too. File Photo by Stephen Shaver/UPI | License Photo June 26 (UPI) -- Tesla CEO Elon Musk has fired the carmaker's vice president of manufacturing and operations following a falloff in auto sales in the nation's largest markets this year. Omead Afshar oversaw more than a half dozen upper-level employees in the company, including Troy Jones, Tesla's vice president of sales in North America, and Joe Ward, vice president of the Europe, Middle East and Africa region. The firing was first reported by Bloomberg News. Afshar is the second high-level employee to leave the company recently. His termination follows the resignation of Milan Kovac, who was the company's head of its Optimus humanoid robotics program. Kovac said in a post on X that he was leaving Tesla to spend more time with his family. Musk later thanked Kovac publicly for his time with the company. In 2022, Afshar was the subject of an internal investigation at Tesla that focused on his involvement in trying to secure construction materials for a secret project for Musk that included hard-to-get glass. Prior to his job as Tesla vice president, Afshar worked for SpaceX, Musk's aerospace company. Afshar's X account, which had not been updated, said he still works for Tesla, and he praised Musk for his leadership and work ethic following the launch of the company's Robotaxi service in Austin, Texas. "Thank you, Elon, for pushing us all," Afshar wrote. Tesla's stock price has dropped 19% this year, and took an especially hard hit following Musk's association with President Donald Trump, who appointed Musk to oversee the Department of Government Efficiency. DOGE took a broad and aggressive approach to eliminating federal employees, downsizing federal agencies and ending diversity, equity and inclusion programs at some of the nation's largest companies and universities. The company sold fewer cars in 2024 than it did in 2023, the first time sales dropped since Tesla began mass producing EVs. Its profits fell 71% in the first quarter of 2025. European sales dropped 28%, and dropped for a fifth straight month in May. The European Automobile Manufacturers Association said buyers are shifting to cheaper Chinese models.